linkstream2 microblog

http://www.the-scientist.com/?articles.amp/articleNo/26614/title/Financial-Growing-Pains-of-a-Biotech/

The Man Who Kicked Off…#Biotech by @CarlZimmer
http://nautil.us/issue/44/luck/the-man-who-kicked-off-the-biotech-revolution H Smith for discovering restriction enzymes + a history of the term

QT:{{”
“Trying to make sense of the failure, Wilcox suggested to Smith that the bacteria were destroying the viral DNA. He based his suggestion on a hypothesis proposed a few years earlier by Werner Arber, a microbiologist at the University of Geneva. Arber speculated that enzymes could restrict the growth of viruses by chopping up their DNA, and dubbed these hypothetical molecules “restriction enzymes.”” “}}

The…Pharma Startup…Silicon Valley Has Totally Missed
http://social.techcrunch.com/2017/01/06/this-millennial-wants-to-build-the-berkshire-hathaway-of-biopharmaceutical-companies-can-he-pull-it-off/ Run by QVT alum; focuses on better incentivizing scientists

$BMY rips up its R&D group…800-plus [affected]
http://www.fiercebiotech.com/story/bristol-myers-rips-its-rd-group-adding-eliminating-and-moving-hundreds/2015-06-25 Trend of pruning spoke cities & growing #hub ones HT @JorgensenWL

QT:{{”
“Bristol-Myers Squibb’s big reorganization fits into the industry’s new model for R&D. Large, scattered groups are out as big
organizations gravitate toward the big hubs. GlaxoSmithKline ($GSK) and Amgen ($AMGN) have offered two recent examples of that trend, which has benefited hubs like Boston/Cambridge and the Bay Area while inflicting painful cuts in outlying areas. Biopharma companies are also concentrating on core areas, sometime shedding early-stage work–reflected in Merck’s ($MRK) recent downsizing at the newly acquired Cubist and the big asset swap that occurred between GlaxoSmithKline and Novartis ($NVS).”
“}}